The Drug Class Impact of Major Patent Expirations

Published by: Decision Resources

Published: Mar. 11, 2009 - 52 Pages

Table of Contents

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

United States

General Environment

Statins

Selective Serotonin Reuptake Inhibitors

Bisphosphonates

Benign Prostatic Hyperplasia Therapies

France

General Environment

Statins

Selective Serotonin Reuptake Inhibitors

Bisphosphonates

Benign Prostatic Hyperplasia Therapies

Germany

General Environment

Statins

Selective Serotonin Reuptake Inhibitors

Bisphosphonates

Benign Prostatic Hyperplasia Therapies

United Kingdom

General Environment

Statins

Selective Serotonin Reuptake Inhibitors

Bisphosphonates

Benign Prostatic Hyperplasia Therapies

Outlook and Implications for the Pharmaceutical Industry

Tables

1. Express Scripts’ Calculations of Actual and Potential Generics Dispensing Rates and Potential Savings, 2007

2. Market Shares in the U.S. Statin Market, July 2003-November 2008

3. Volume Changes in the U.S. Statin Market, July 2003-November 2008

4. Market Shares in the U.S. Selective Serotonin Reuptake Inhibitor Market, July 2003-November 2008

5. Volume Changes in the U.S. Selective Serotonin Reuptake Inhibitor Market, July 2003-November 2008

6. Market Shares in the U.S. Bisphosphonate Market, July 2003-November 2008

7. Volume Changes in the U.S. Bisphosphonate Market, July 2003-November 2008

8. Market Shares in the U.S. Benign Prostatic Hyperplasia Therapy Market, July 2003-November 2008

9. Volume Changes in the U.S. Benign Prostatic Hyperplasia Therapy Market, July 2003-November 2008

10. Generics Penetration Rates for Select Compounds in France, December 2007 and April 2008

11. Market Shares in the French Statin Market, 2002-2007

12. Volume Changes in the French Statin Market, 2002-2007

13. Market Shares in the French Selective Serotonin Reuptake Inhibitor Market, 2002-2007

14. Volume Changes in the French Selective Serotonin Reuptake Inhibitor Market, 2002-2007

15. Market Shares in the French Bisphosphonate Market, 2002-2007

16. Volume Changes in the French Bisphosphonate Market, 2002-2007

17. Market Shares in the French Benign Prostatic Hyperplasia Therapy Market, 2002-2007

18. Volume Changes in the French Benign Prostatic Hyperplasia Therapy Market, 2002-2007

19. Market Shares in the German Statin Market, 2002-2007

20. Volume Changes in the German Statin Market, 2002-2007

21. Market Shares in the German Selective Serotonin Reuptake Inhibitor Market, 2002-2007

22. Volume Changes in the German Selective Serotonin Reuptake Inhibitor Market, 2002-2007

23. Market Shares in the German Bisphosphonate Market, 2002-2007

24. Volume Changes in the German Bisphosphonate Market, 2002-2007

25. Market Shares in the German Benign Prostatic Hyperplasia Therapy Market, 2002-2007

26. Volume Changes in the German Benign Prostatic Hyperplasia Therapy Market, 2002-2007

27. Market Shares in the English Statin Market, 2002-2007

28. Volume Changes in the English Statin Market, 2002-2007

29. Market Shares in the English Selective Serotonin Reuptake Inhibitor Market, 2002-2007

30. Volume Changes in the English Selective Serotonin Reuptake Inhibitor Market, 2002-2007

31. Market Shares in the English Bisphosphonate Market, 2002-2007

32. Volume Changes in the English Bisphosphonate Market, 2002-2007

33. Market Shares in the English Benign Prostatic Hyperplasia Therapy Market, 2002-2007

34. Volume Changes in the English Benign Prostatic Hyperplasia Therapy Market, 2002-2007

Abstract

• A leading pharmacy benefi t management company (PBM) in the United States, calculated that, in 2007, maximizing the use of generics could have saved its members a combined total of more than $20 billion from 13 leading drug classes. How did the launch of generic simvastatin impact other statins, including the market leader? What effect have patent expirations had on prescribing patterns in other drug classes? How have new drugs launched into drug classes subject to generics competition fared?
• The French government has introduced numerous measures to stimulate the nation’s immature generics market. To what extent have these reforms changed patterns of generic erosion in France? How have French physicians responded to targets for generic penetration?
• The German government has relied heavily on reference pricing and related measures to curb pharmaceutical expenditures. How does recent history in the statin market demonstrate the hazards of defying reference pricing? What effect do strict budgetary constraints have on German physicians’ prescribing behavior?
• Generic drugs dominate the cost-conscious U.K. pharmaceutical market and continue to increase their market share. What local measures are used to maximize the use of generics? How have government policies and the National Institute for Health and Clinical Excellence contributed to the growth of generics? How have new drugs fared in markets already subject to generics competition?

• Major markets: United States; France; Germany; United Kingdom; international trends.
• Drug classes: statins; selective serotonin reuptake inhibitors; bisphosphonates; benign prostatic hyperplasia therapies.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.